Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mark Brown

Physician Assistant, Medical Fairhope, AL Physician Assistant

NPI 1578747515 CMS profile 10525990

7550 Assunta Ct, Fairhope, AL 36532

Open in the dashboard

General payments

$4,709

263 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Brown of Fairhope, AL is reported in the CMS Open Payments database as having received $4,709 across 263 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $698 38
2024 General $849 39
2023 General $955 57
2022 General $1,044 60
2021 General $1,162 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Brown
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Mark Brown were reported at $698. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Mark Brown Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,162 $156 $41–$563 $132
2022 $1,044 $185 $55–$649 $149
2023 $955 $199 $58–$717 $160
2024 $849 $206 $62–$740 $164
2025 $698 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,124 69 payments
  2. Sun Pharmaceutical Industries Inc. $672 39 payments
  3. Janssen Biotech, Inc. $454 26 payments
  4. UCB, Inc. $343 13 payments
  5. LEO Pharma Inc. $340 25 payments
  6. Lilly USA, LLC $293 13 payments
  7. Dermavant Sciences, Inc. $187 15 payments
  8. Genzyme Corporation $165 9 payments
  9. E.R. Squibb & Sons, L.L.C. $165 8 payments
  10. Novartis Pharmaceuticals Corporation $155 8 payments
  11. Other $811 38 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,423 259 payments
  2. Education $286 4 payments
Products named General payments · program years 2021–2025
  1. SKYRIZI $551 33 payments
  2. ILUMYA $427 30 payments
  3. RINVOQ $405 24 payments
  4. TREMFYA $346 19 payments
  5. ADBRY $287 22 payments
  6. DUPIXENT $284 11 payments
  7. TALTZ $241 11 payments
  8. Bimzelx $187 7 payments
  9. VTAMA $187 15 payments
  10. SIMPONI ARIA $184 10 payments
  11. Other $2,528 132 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,221

Median for Physician Assistant: 241

Drug cost

$851,742

Median for Physician Assistant: $4,110

Branded share of claims

14.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 16 $334,499
Dupixent Pen Dupilumab Brand 37 $138,063
Taltz Autoinjector Ixekizumab Brand 15 $104,266
Rinvoq Upadacitinib Brand 15 $93,778
Cosentyx Sensoready (2 Pens) Secukinumab Brand 11 $79,372
Otezla Apremilast Brand 16 $74,141
Fluocinonide Generic 94 $5,049
Doxycycline Hyclate Generic 160 $4,670
Clobetasol Propionate Generic 89 $3,958
Ketoconazole Generic 95 $1,648

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$128,344

Of which drugs: $174

Medicare patients

794

Average age 76

Services billed

4,399

384 women, 410 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 36%
Diabetes 25%
Chronic kidney disease 21%
Atrial fibrillation 18%
Depression 17%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 22 139 $97

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $137
$137 15 —
OPZELURA
  • Incyte Corporation $105
$105 — —
Bimzelx
  • UCB, Inc. $72
$72 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $69
$69 11 —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $66
$66 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

263 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record